International Biotechnology Trust (CHIX:IBTL) Change In Working Capital : £0.05 Mil (TTM As of Feb. 2025)

View and export this data going back to 2015. Start your Free Trial

What is International Biotechnology Trust Change In Working Capital?

International Biotechnology Trust's change in working capital for the quarter that ended in Feb. 2025 was £1.21 Mil.

International Biotechnology Trust's change in working capital for the fiscal year that ended in Aug. 2024 was £-0.73 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

International Biotechnology Trust Change In Working Capital Historical Data

The historical data trend for International Biotechnology Trust's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

International Biotechnology Trust Change In Working Capital Chart

International Biotechnology Trust Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

Change In Working Capital

Get a 7-Day Free Trial

-62.98

0.70

19.24

1.05

-0.73

International Biotechnology Trust Semi-Annual Data
	Aug15	Feb16	Aug16	Feb17	Aug17	Feb18	Aug18	Feb19	Aug19	Feb20	Aug20	Feb21	Aug21	Feb22	Aug22	Feb23	Aug23	Feb24	Aug24	Feb25
Change In Working Capital	Get a 7-Day Free Trial															5.17	-4.11	0.43	-1.16	1.21

International Biotechnology Trust Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Feb. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.05 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

International Biotechnology Trust Change In Working Capital Related Terms

Thank you for viewing the detailed overview of International Biotechnology Trust's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

International Biotechnology Trust Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » International Biotechnology Trust PLC (CHIX:IBTl) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

IBT:UK

Address

1 London Wall Place, London, GBR, EC2Y 5AU

Website

https://www.ibtplc.com

International Biotechnology Trust PLC is an investment trust company. It aims at achieving long-term capital growth by investing in biotechnology and other life sciences companies. It seeks to achieve its objective by investing in a diversified portfolio of companies which has good growth prospects. It focuses on investments in biotechnology companies which are engaged in on drug discovery and development, medical devices companies and healthcare services provider. The invests in various financial instruments such as equities, index-linked securities, debt securities, cash deposits, money market instruments ,and foreign currency exchange transactions. Its revenue comprises of dividend, interest and other income from investment made.